Ronald Park, Ambys Medicines CEO
Third Rock's Ambys closes a megaround with the clinic still a ways off for its regenerative cells for liver disease
When Ambys Medicines, a Third Rock Ventures-backed regenerative play, launched in 2018, it came with some serious fanfare for its liver disease-focused approach. Now, after years of quiet development, the company has a new trough of money to play with as it slowly approaches the clinic.
Ambys closed $107 million in total Series A funding — with a $47 million extension add — Tuesday with a lead program creating healthy versions of liver cells still more than a year from the clinic, the biotech said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
